Just because they presented data on the original unblinded 19 patients for B-OM, does not mean more patients have not been added. Due to the blinding process, data can not be analyzed on a rolling basis.
Regardless, the highly encouraging previously released B-OM data, in addition to the newly released B-UP date, make a very compelling story regarding its anti-inflammatory as well as previously known antibiotic properties.
I expect after today's news, IPIX will be meeting with many of the large pharma companies over the next 1 to 6 months, and will evaluate the best deal to increase shareholder value.
This is an exciting time and the best is yet to come!
News 
Market Data 
Discover 
